Estimating health utilities and quality adjusted life years in seasonal affective disorder research

被引:3
作者
Freed, Michael C.
Rohan, Kelly J.
Yates, Brian T.
机构
[1] American Univ, Dept Psychol, Washington, DC 20016 USA
[2] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA
关键词
quality adjusted life year; cost-effectiveness; depression; seasonal affective disorder; health utility; COST-EFFECTIVENESS ANALYSIS; PRIMARY-CARE; LIGHT THERAPY; DEPRESSION; PREFERENCES;
D O I
10.1016/j.jad.2006.09.038
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Seasonal affective disorder (SAD) episodes will recur annually without effective intervention. Effectiveness of such interventions is traditionally measured with depression-specific tools (e.g., Beck Depression Inventory 2nd Edition; BDI-II). In a climate of potentially scarce resources, generic outcomes, such as Quality Adjusted Life Years (QALYs), are recommended for cost-effectiveness research. For treatments to be deemed cost-effective, they must show effectiveness relative to each other and relative to interventions across other disorders. To date, QALYs have not been used to determine effectiveness of SAD treatments. Given the recurrent nature of SAD, QALYs, which weight quality of life with time, are an ideal SAD treatment outcome. Method: A method to assess QALYs for SAD was developed using pilot clinical trial data. The method estimated health utilities, a measure of quality of life for a QALY, by anchoring pilot BDI-II data from the SAD clinical trial with previously derived health utilities for nonseasonal depression. Results: Relative to no treatment, median QALYs gained ranged from 0.11-0.18 over 1 year, depending on the intervention assessed. Discussion: Any treatment for SAD must compete with spontaneous spring remission, as illness severity attenuates in the spring. Limitations: Health utilities were estimated from the depression literature, and potential side effects from SAD treatments were not included in the estimates. The clinical trial time horizon was limited to 1-year. Conclusions: The proposed method offers researchers a tool to transform SAD efficacy data into a generic outcome for use in cost-effectiveness analysis of SAD treatments. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [11] Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening
    Davidovic, Masa
    Zielonke, Nadine
    Lansdorp-Vogelaar, Iris
    Segnan, Nereo
    Koning, Harry J. de
    Heijnsdijk, Eveline AM.
    VALUE IN HEALTH, 2021, 24 (03) : 353 - 360
  • [12] Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial
    McClure, Nathan S.
    Paulden, Mike
    Ohinmaa, Arto
    Johnson, Jeffrey A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (09) : 1441 - 1451
  • [13] Quality-adjusted life years in cancer: pros, cons, and alternatives
    Woodward, R. M.
    Menzin, J.
    Neumann, P. J.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (01) : 12 - 19
  • [14] Utilitarianism and the Measurement and Aggregation of Quality – Adjusted Life Years
    Paul Dolan
    Health Care Analysis, 2001, 9 : 65 - 76
  • [15] Not all "quality-adjusted life years" are equal
    Marra, C. A.
    Marion, S. A.
    Guh, D. P.
    Najafzadeh, M.
    Wolfe, F.
    Esdaile, J. M.
    Clarke, A. E.
    Gignac, M. A.
    Anis, A. H.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2007, 60 (06) : 616 - 624
  • [16] Quality-adjusted life years: how useful in medico economic studies
    Brauer, CA
    Neumann, PJ
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (06) : 603 - 607
  • [17] Methods and issues associated with the use of quality-adjusted life-years
    Revicki, Dennis A.
    Lenderking, William R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (01) : 105 - 114
  • [18] Quality adjusted life years based on health and consumption: A summary wellbeing measure for cross-sectoral economic evaluation
    Cookson, Richard
    Skarda, Ieva
    Cotton-Barratt, Owen
    Adler, Matthew
    Asaria, Miqdad
    Ord, Toby
    HEALTH ECONOMICS, 2021, 30 (01) : 70 - 85
  • [19] The Seasonal Health Questionnaire: a preliminary validation of a new instrument to screen for Seasonal Affective Disorder
    Thompson, C
    Cowan, A
    JOURNAL OF AFFECTIVE DISORDERS, 2001, 64 (01) : 89 - 98
  • [20] Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder
    Revicki, Dennis A.
    Brandenburg, Nancy
    Matza, Louis
    Hornbrook, Mark C.
    Feeny, David
    QUALITY OF LIFE RESEARCH, 2008, 17 (10) : 1285 - 1294